The Mouse Genetics Facility was established in 1999 in response to the increasing need of Cancer Center investigators for analysis of gene function in mouse models, and has received Cancer Center support since 2002. Since the last renewal, the Facility has changed leadership, with Dr. Anthony Capobianco now the scientific director of the Facility and Dr. Ping Jiang the facility director. In this funding period, the Institute has invested $167,450 for new and upgraded equipment and renovated laboratory and animal facility space. The Facility provides highly efficient production of both transgenic and knock-out/knock-in (KO/KI) mice, plus it provides a unique resource and expertise in embryonic stem (ES) cell cultivation and engineering, which benefits Cancer Center investigators generating both in vivo and in vitro murine models of cancer. Current services are aligned with the research objectives of the Cancer Center programs and include: (1) production of transgenic mice by pronuclear microinjection of DNA transgene constructs;(2) generation of genetargeted 129 and C57BL mouse ES cell clones;(3) production of chimeric mice derived from microinjection of gene-targeted ES cells into blastocysts;(4) rederivation of mouse lines by embryo transfer;and (5) ES cell cultivation and engineering. Since 2006, the Facility has produced 15 lines of transgenic mice, successfully generated 11 lines of KO/KI mouse ES cell clones, and produced 8 lines of chimeric KO/KI mice. In addition, the Facility successfully rederived a line of an engineered mouse strain and will offer a mouse embryo cryopreservation service in 2008. The Facility is actively collaborating with Cancer Center investigators to utilize its mouse ES cell technology, with the aim of using human ES cells as a vehicle to derive mutant or disease specific cell lineages as a new human disease model system. Goals for the Facility over the next funding period include developing lentiviral mediated transgenesis for some strains of mice that are difficult to produce with DNA microinjection, developing use of tetraploid complementation as an efficient approach to produce chimeras from injections of ES cells of C57BL origin into blastocysts, and establishing human ES cell cultivation and engineering as a routine service.

Public Health Relevance

Production of genetically modified mice permits cancer center investigators the possibility to create mice that carry identical genetic changes seen in human tumors to determine if those changes are sufficient to copy the characteristics of the human tumor. Non-animal systems are unable to examine a mutant cancer gene in such a rich context.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA010815-40
Application #
7945024
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-15
Project End
2014-02-28
Budget Start
2009-04-15
Budget End
2010-02-28
Support Year
40
Fiscal Year
2009
Total Cost
$166,732
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Li, Heng; Wang, Zhize; Xiao, Wei et al. (2018) Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients. Mod Pathol 31:198-208
Shastrula, Prashanth K; Rice, Cory T; Wang, Zhuo et al. (2018) Structural and functional analysis of an OB-fold in human Ctc1 implicated in telomere maintenance and bone marrow syndromes. Nucleic Acids Res 46:972-984
Duperret, Elizabeth K; Trautz, Aspen; Ammons, Dylan et al. (2018) Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice. Clin Cancer Res 24:1190-1201
Heppt, Markus V; Wang, Joshua X; Hristova, Denitsa M et al. (2018) MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression. J Invest Dermatol 138:141-149
Wu, Shuai; Fatkhutdinov, Nail; Fukumoto, Takeshi et al. (2018) SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun 9:4116
Ecker, Brett L; Kaur, Amanpreet; Douglass, Stephen M et al. (2018) Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. Cancer Discov :
Abdel-Mohsen, Mohamed; Kuri-Cervantes, Leticia; Grau-Exposito, Judith et al. (2018) CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med 10:
Fukumoto, Takeshi; Magno, Elizabeth; Zhang, Rugang (2018) SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications. Mol Cancer Res 16:1819-1825
Ca├▒adas, Israel; Thummalapalli, Rohit; Kim, Jong Wook et al. (2018) Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24:1143-1150
Basu, Subhasree; Gnanapradeepan, Keerthana; Barnoud, Thibaut et al. (2018) Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1?. Genes Dev 32:230-243

Showing the most recent 10 out of 741 publications